AGANEPAG

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H31NO4S
Molecular Weight	429.572
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC[C@H](O)C1=CC=C(C=C1)N2[C@@H](CCCC3=CC=C(S3)C(O)=O)CCC2=O

InChI

InChIKey=WXWCSPFQIXPFLD-RXVVDRJESA-N

InChI=1S/C24H31NO4S/c1-2-3-4-8-21(26)17-9-11-19(12-10-17)25-18(13-16-23(25)27)6-5-7-20-14-15-22(30-20)24(28)29/h9-12,14-15,18,21,26H,2-8,13,16H2,1H3,(H,28,29)/t18-,21-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D09863 | https://www.ncbi.nlm.nih.gov/pubmed/29669171https://www.genome.jp/dbget-bin/www_bget?dr:D09862https://patents.google.com/patent/WO2014078434A1 | https://www.genome.jp/dbget-bin/www_bget?dr:D09861

Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention. Aganepag is an antiglaucoma agent.

Originator

Approval Year

PubMed

Title	Date	PubMed
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.	2019 Apr	29669171

Patents

Sample Use Guides

In Vitro Use Guide

Aganepag (Compound 3) is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM

Name

Type

Language

AGANEPAG

Official Name

English

Aganepag [WHO-DD]

Common Name

English

AGN-210937

Code

English

5-(3-((2S)-1-(4-((1S)-1-HYDROXYHEXYL)PHENYL)-5-OXOPYRROLIDIN-2-YL)PROPYL)THIOPHENE-2- CARBOXYLIC ACID

Systematic Name

English

AGANEPAG [USAN]

Common Name

English

2-THIOPHENECARBOXYLIC ACID, 5-(3-((2S)-1-(4-((1S)-1-HYDROXYHEXYL)PHENYL)-5-OXO-2- PYRROLIDINYL)PROPYL)-

Common Name

English

aganepag [INN]

Common Name

English

Code System Code Type Description

USAN

YY-24